89 related articles for article (PubMed ID: 18615772)
1. The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?
Marignol L; Robson T; McCarthy HO; Worthington J; Murray MM; Hollywood D; Lawler M; Hirst DG
J Gene Med; 2008 Sep; 10(9):1032-8. PubMed ID: 18615772
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
3. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ
Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
6. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy.
Boothman DA; Lee IW; Sahijdak WM
Radiat Res; 1994 Apr; 138(1 Suppl):S68-71. PubMed ID: 8146331
[TBL] [Abstract][Full Text] [Related]
7. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
8. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
9. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector.
Laurie KL; Blundell MP; Baxendale HE; Howe SJ; Sinclair J; Qasim W; Brunsberg U; Thrasher AJ; Holmdahl R; Gustafsson K
Gene Ther; 2007 Dec; 14(23):1623-31. PubMed ID: 17851547
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.
Worthington J; Robson T; Scott S; Hirst D
Gene Ther; 2005 Oct; 12(19):1417-23. PubMed ID: 15902277
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer gene therapy and the role of radiation.
Kaminski JM; Nguyen K; Buyyounouski M; Pollack A
Cancer Treat Rev; 2002 Feb; 28(1):49-64. PubMed ID: 12027414
[TBL] [Abstract][Full Text] [Related]
12. Two conserved regions within the tissue-type plasminogen activator gene promoter mediate regulation by brain-derived neurotrophic factor.
Daniel PB; Lux W; Samson AL; Schleuning WD; Niego B; Weiss TW; Tjärnlund-Wolf A; Medcalf RL
FEBS J; 2007 May; 274(9):2411-23. PubMed ID: 17419735
[TBL] [Abstract][Full Text] [Related]
13. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
16. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain.
Liu BH; Yang Y; Paton JF; Li F; Boulaire J; Kasparov S; Wang S
Mol Ther; 2006 Dec; 14(6):872-82. PubMed ID: 16904943
[TBL] [Abstract][Full Text] [Related]
17. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells.
Borrelli MJ; Schoenherr DM; Wong A; Bernock LJ; Corry PM
Cancer Res; 2001 Feb; 61(3):1113-21. PubMed ID: 11221841
[TBL] [Abstract][Full Text] [Related]
18. Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors.
Glushakova LG; Timmers AM; Pang J; Teusner JT; Hauswirth WW
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3505-13. PubMed ID: 16877422
[TBL] [Abstract][Full Text] [Related]
19. NF1 regulatory element functions as a repressor of tissue plasminogen activator expression.
Pham NL; Franzen A; Levin EG
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):982-7. PubMed ID: 15044208
[TBL] [Abstract][Full Text] [Related]
20. Salmonella promoters preferentially activated inside tumors.
Arrach N; Zhao M; Porwollik S; Hoffman RM; McClelland M
Cancer Res; 2008 Jun; 68(12):4827-32. PubMed ID: 18559530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
